A Study of RO4917523 in Patients With Fragile X Syndrome
Public ClinicalTrials.gov record NCT01517698. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Study identification
- NCT ID
- NCT01517698
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Enrollment
- 185 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- RO4917523 0.5 mg Drug
- RO4917523 1.5 mg Drug
Drug
Eligibility (public fields only)
- Age range
- 14 Years to 50 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2012
- Primary completion
- Mar 31, 2014
- Completion
- Mar 31, 2014
- Last update posted
- Jul 10, 2016
2012 – 2014
United States locations
- U.S. sites
- 20
- U.S. states
- 17
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Phoenix | Arizona | 85006 | — |
| Not listed | Long Beach | California | 90806 | — |
| Not listed | Sacramento | California | 95817 | — |
| Not listed | Aurora | Colorado | 80045 | — |
| Not listed | Washington D.C. | District of Columbia | 20010 | — |
| Not listed | Decatur | Georgia | 30033 | — |
| Not listed | Chicago | Illinois | 60612 | — |
| Not listed | Iowa City | Iowa | 52242-1083 | — |
| Not listed | Louisville | Kentucky | 40202 | — |
| Not listed | Baltimore | Maryland | 21205 | — |
| Not listed | Worcester | Massachusetts | 01655 | — |
| Not listed | New York | New York | 10029 | — |
| Not listed | Staten Island | New York | 10314 | — |
| Not listed | Durham | North Carolina | 27710 | — |
| Not listed | Cincinnati | Ohio | 45229 | — |
| Not listed | Media | Pennsylvania | 19063 | — |
| Not listed | Nashville | Tennessee | 37203 | — |
| Not listed | Houston | Texas | 77030 | — |
| Not listed | San Antonio | Texas | 78258 | — |
| Not listed | Seattle | Washington | 98145 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 31 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01517698, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 10, 2016 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01517698 live on ClinicalTrials.gov.